Business Context and Reporting Period
This Form 8-K is a current report filed by Pluristem Therapeutics Inc. (Pluri) on January 9, 2018, covering events that occurred on January 8 and January 9, 2018. The company is a biopharmaceutical entity focused on cell therapy, headquartered in Haifa, Israel.
Key Financial Metrics
The filing details a specific asset disposition rather than full-period financial statements. Key metrics include:
- Asset Sale Proceeds: Approximately $10.5 million in net proceeds from the sale of 400,368 shares of CHA Biotech Co. Ltd.
- Net Gain: $6.2 million recognized from the transaction.
- Revenue/Profit/Cash Flow: The filing does not provide comprehensive revenue, operating profit, or cash flow data for the period. It only specifies the expected recognition of the $6.2 million gain in the statement of operations for the nine months ending March 31, 2018.
- Debt and Liquidity: The filing text does not provide clear values for total debt, cash balances, or liquidity ratios.
Material Changes
The primary material change is the divestiture of the company's entire holding in CHA Biotech Co. Ltd. Previously classified as "Marketable Securities" (available-for-sale), these assets were sold on the open market, resulting in a significant one-time financial gain. Additionally, the company received regulatory clearance for an Expanded Access Program (EAP) for its PLX-PAD cell treatment, marking a shift in the availability of its investigational product for specific patient populations.
Guidance, Outlook, and Risks
Management Commentary and Outlook: Management expects to recognize the $6.2 million net gain in the upcoming fiscal quarter. The FDA clearance of the EAP allows the PLX-PAD therapy to be used for a limited number of Rutherford Category 5 Critical Limb Ischemia (CLI) patients in the U.S. who are unsuitable for revascularization or clinical trials.
Risks and Contingencies: The filing includes a standard warning regarding forward-looking statements. Key risks cited include:
- Delays or obstacles in clinical trials.
- Potential lack of regulatory approval for products.
- Scientific validation challenges and translation of lab results to surgical settings.
- Competition, pricing pressure, and market share loss.
- Patent insufficiency and potential product harm to recipients.
Investor Verification Checklist
- Verify the exact timing of the $6.2 million gain recognition in the Q1 2018 financial statements.
- Confirm the number of patients enrolled in the newly approved Expanded Access Program (EAP).
- Review the company's updated cash position post-transaction to assess runway for ongoing clinical trials.
- Monitor regulatory communications regarding the Phase III clinical study for PLX-PAD, as the EAP is a separate pathway for unsuitable patients.